The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN) as its February 2010 "Stock to Study" and C.R. Bard, Inc. (NYSE: BCR) as its February 2010 "Undervalued Stock" for investors' informational and educational use.
"The committee chose Allergan because of growth opportunities involving its flagship drug Botox and other products as well as a reasonable current valuation," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the committee believes C.R. Bard's business should benefit when hospitals begin restocking supplies." Check BetterInvesting Magazine's February issue for more details about these selections.